<DOC>
	<DOCNO>NCT00266032</DOCNO>
	<brief_summary>The purpose study determine safety efficacy long-cycle regimens oral contraceptive .</brief_summary>
	<brief_title>Study Safety Efficacy Oral Contraceptive Long Cycles</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG ( BSP AG ) , Germany . Bayer Schering Pharma AG , Germany sponsor trial . The previously post secondary Outcome Measure `` Parameters safety tolerability '' remove result post covered Adverse Event section .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Betadex</mesh_term>
	<criteria>Healthy woman desire contraception smoker â‰¤ 30 Years old Contraindication use hormonal contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>